Jefferies Says Watch for Bottom in Endo Pharma (ENDP)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- Wall St ends higher on cool inflation data, strong earnings
- U.S. headline producer inflation posts first one-month decrease since August 2025
- PayPal rallies 20% on report Stripe, Advent made $53 billion bid
- Oil prices make small gain on smaller US inventory draw
- ASML capacity upgrade soothes AI chip bottleneck fears
Endo Pharmaceuticals Holdings (ENDP) Tops Q3 EPS by 2c; Adjusts FY12 Outlook
November 5, 2012 7:04 AM ESTEndo Pharmaceuticals Holdings (NASDAQ: ENDP) reported Q3 EPS of $1.28, $0.02 better than the analyst estimate of $1.26. Revenue for the quarter came in at $750 million versus the consensus estimate of $788.53 million.
Sees FY2012 EPS of $5.00-$5.10, versus the consensus of $5.03. Endo Pharmaceuticals Holdings sees FY2012... More
